Abstract
Introduction: Tumor recurrence in choroidal melanoma has been associated with decreased overall survival due to metastatic spreading. To detect risk factors of local recurrence and side effects, we analyzed tumor planning and treatment parameters in patients with recurrence of choroidal melanoma after treatment with robotic-assisted radiosurgery (CyberKnife). Methods: Six hundred ninety-four patients treated with CyberKnife between 2005 and 2019 were retrospectively reviewed. Age, gender, best-corrected visual acuity, tumor height, and diameter were recorded. Treatment planning and radiation doses were reviewed. Salvage therapy, overall survival, metastasis, and complications were recorded. Results: Seventy-four patients showed local recurrence. Local recurrence occurred after 42.1 months post CyberKnife treatment (mean; range: 5–100 months). Fourteen out of 74 patients (18.9%) died during follow-up. Recurrence treatment included enucleation in 51 patients (68.9%) and radiosurgery in 19 patients (25.7%). Treatment planning without contrast medium MRI, radiation dose of less than 21 Gy, and insufficient margin delineation were identified as risk factors incrementing local control. Discussion: Robotic-assisted radiosurgery (CyberKnife) is a suitable treatment option for large choroidal melanoma up to 12 mm. Patients with significantly better visual acuity received repeat CyberKnife treatment as salvage therapy and showed an eye retention rate of 81%.
References
1.
Collaborative Ocular Melanoma Study Group
. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28
. Arch Ophthalmol
. 2006
;124
(12
):1684
–93
.2.
Chang
MY
, McCannel
TA
. Local treatment failure after globe-conserving therapy for choroidal melanoma
. Br J Ophthalmol
. 2013
;97
(7
):804
–11
.3.
Char
DH
, Kroll
S
, Phillips
TL
. Uveal melanoma. Growth rate and prognosis
. Arch Ophthalmol
. 1997
;115
(8
):1014
–8
.4.
Vrabec
TR
, Augsburger
JJ
, Gamel
JW
, Brady
LW
, Hernandez
C
, Woodleigh
R
. Impact of local tumor relapse on patient survival after cobalt 60 plaque radiotherapy
. Ophthalmology
. 1991
;98
(6
):984
–8
.5.
Char
DH
, Castro
JR
, Kroll
SM
, Irvine
AR
, Quivey
JM
, Stone
RD
. Five-year follow-up of helium ion therapy for uveal melanoma
. Arch Ophthalmol
. 1990
;108
(2
):209
–14
.6.
Fontanesi
J
, Meyer
D
, Xu
S
, Tai
D
. Treatment of choroidal melanoma with I-125 plaque
. Int J Radiat Oncolo Biol Phys
. 1993
;26
(4
):619
–23
.7.
Fontanesi
J
, Hetzler
D
, Ross
J
. Effect of dose rate on local control and complications in the reirradiation of head and neck tumors with interstitial iridium-192
. Int J Radiat Oncol Biol Phys
. 1989
;17
(2
):365
–9
.8.
Egan
KM
, Gragoudas
ES
, Seddon
JM
, Glynn
RJ
, Munzenreider
JE
, Goitein
M
, . The risk of enucieatlon after proton beam irradiation of uveal melanoma
. Ophthalmology
. 1989
;96
(9
):1377
–83
; discussion 82–3
. https://doi.org/10.1016/s0161-6420(89)32738-2.9.
Finger
PT
. Radiation therapy for choroidal melanoma
. Surv Ophthalmol
. 1997
;42
(3
):215
–32
.10.
Tabandeh
H
, Chaudhry
NA
, Murray
TG
, Ehlies
F
, Hughes
R
, Scott
IU
, . Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma
. Am J Ophthalmol
. 2000
;129
(2
):199
–204
.11.
Simonová
G
, Novotný
J
Jr, Liscák
R
, Pilbauer
J
. Leksell gamma knife treatment of uveal melanoma
. J Neurosurg
. 2002
;97
(5 Suppl
):635
–9
.12.
Wackernagel
W
, Holl
E
, Tarmann
L
, Mayer
C
, Avian
A
, Schneider
M
, . Local tumour control and eye preservation after gamma-knife radiosurgery of choroidal melanomas
. Br J Ophthalmol
. 2014
;98
(2
):218
–23
.13.
Dunavoelgyi
R
, Dieckmann
K
, Gleiss
A
, Sacu
S
, Kircher
K
, Georgopoulos
M
, . Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007
. Int J Radiat Oncol Biol Phys
. 2011
;81
(1
):199
–205
.14.
Krema
H
, Somani
S
, Sahgal
A
, Xu
W
, Heydarian
M
, Payne
D
, . Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up
. Br J Ophthalmol
. 2009
;93
(9
):1172
–6
.15.
Modorati
G
, Miserocchi
E
, Galli
L
, Picozzi
P
, Rama
P
. Gamma knife radiosurgery for uveal melanoma: 12 years of experience
. Br J Ophthalmol
. 2009
;93
(1
):40
–4
.16.
Accuracy of diagnosis of choroidal melanomas in the collaborative ocular melanoma study. COMS report no. 1
. Arch Ophthalmol
. 1990
;108
(9
):1268
–73
.17.
Muacevic
A
, Nentwich
M
, Wowra
B
, Staerk
S
, Kampik
A
, Schaller
U
. Development of a streamlined, non-invasive robotic radiosurgery method for treatment of uveal melanoma
. Technol Cancer Res Treat
. 2008
;7
(5
):369
–73
.18.
Finger
PT
, Kurli
M
. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy
. Br J Ophthalmol
. 2005
;89
(6
):730
–8
.19.
Bechrakis
NE
, Petousis
V
, Willerding
G
, Krause
L
, Wachtlin
J
, Stroux
A
, . Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate
. Br J Ophthalmol
. 2010
;94
(4
):460
–6
.20.
McCannel
TA
, Chang
MY
, Burgess
BL
. Multi-year follow-up of fine-needle aspiration biopsy in choroidal melanoma
. Ophthalmology
. 2012
;119
(3
):606
–10
.21.
Leonard
KL
, Gagne
NL
, Mignano
JE
, Duker
JS
, Bannon
EA
, Rivard
MJ
. A 17-year retrospective study of institutional results for eye plaque brachytherapy of uveal melanoma using (125)I, (103)Pd, and (131)Cs and historical perspective
. Brachytherapy
. 2011
;10
(4
):331
–9
.22.
Chang
MY
, Kamrava
M
, Demanes
DJ
, Leu
M
, Agazaryan
N
, Lamb
J
, . Intraoperative ultrasonography-guided positioning of iodine 125 plaque brachytherapy in the treatment of choroidal melanoma
. Ophthalmology
. 2012
;119
(5
):1073
–7
.23.
Shah
NV
, Houston
SK
, Murray
TG
, Markoe
AM
. Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review
. Clin Ophthalmol
. 2012
;6
:447
–52
.24.
Singh
AD
, Turell
ME
, Topham
AK
. Uveal melanoma: trends in incidence, treatment, and survival
. Ophthalmology
. 2011
;118
(9
):1881
–5
.25.
Bensoussan
E
, Thariat
J
, Maschi
C
, Delas
J
, Schouver
ED
, Hérault
J
, . Outcomes after proton beam therapy for large choroidal melanomas in 492 patients
. Am J Ophthalmol
. 2016
;165
:78
–87
.26.
Liegl
R
, Schmelter
V
, Fuerweger
C
, Foerster
MH
, Muacevic
A
, Priglinger
SG
, . Robotic cyberknife radiosurgery for ciliary body melanoma
. Ophthalmol Retina
. 2020
;4
(9
):954
–6
.27.
Jaarsma-Coes
MG
, Goncalves Ferreira
TA
, van Haren
GR
, Marinkovic
M
, Beenakker
JWM
. MRI enables accurate diagnosis and follow-up in uveal melanoma patients after vitrectomy
. Melanoma Res
. 2019
;29
(6
):655
–9
.28.
Kivelä
T
, Eskelin
S
, Mäkitie
T
, Summanen
P
. Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance
. Invest Ophthalmol Vis Sci
. 2001
;42
(9
):2085
–93
.29.
Beenakker
JWM
, Ferreira
TA
, Soemarwoto
KP
, Genders
SW
, Teeuwisse
WM
, Webb
AG
. Clinical evaluation of ultra-high-field MRI for three-dimensional visualisation of tumour size in uveal melanoma patients, with direct relevance to treatment planning
. Magn Reson Mater Phy
. 2016
;29
(3
):571
–7
.30.
Foti
PV
, Longo
A
, Reibaldi
M
, Russo
A
, Privitera
G
, Spatola
C
, . Uveal melanoma: quantitative evaluation of diffusion-weighted MR imaging in the response assessment after proton-beam therapy, long-term follow-up
. Radiol Med
. 2017
;122
(2
):131
–9
.31.
Hall
EJ
, Brenner
DJ
. The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies
. Int J Radiat Oncol Biol Phys
. 1993
;25
(2
):381
–5
.© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.
